MGMT methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma

Elizabeth R. Gerstner; S. Yip; D. L. Wang; D. N. Louis; A. J. Iafrate; T. T. Batchelor

doi:10.1212/WNL.0b013e3181bf9907

MGMT methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma

Elizabeth R. Gerstner
, S. Yip
, D. L. Wang
, D. N. Louis
, A. J. Iafrate
, T. T. Batchelor

Division of Emergency Medicine

Research output: Contribution to journal › Article › peer-review

96 Scopus citations

Original language	English
Pages (from-to)	1509-1510
Number of pages	2
Journal	Neurology
Volume	73
Issue number	18
DOIs	https://doi.org/10.1212/WNL.0b013e3181bf9907
State	Published - Nov 2009

Access to Document

10.1212/WNL.0b013e3181bf9907

Cite this

@article{58b75649766141ba9899242ea00f4ae6,

title = "MGMT methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma",

author = "Gerstner, \{Elizabeth R.\} and S. Yip and Wang, \{D. L.\} and Louis, \{D. N.\} and Iafrate, \{A. J.\} and Batchelor, \{T. T.\}",

note = "Funding Information: Disclosure: Dr. Gerstner is funded by a K12 training grant (awarded to Dr. Batchelor). Dr. Yip is funded by a Royal College of Physicians and Surgeons of Canada Clinical Investigator Fellowship. D.L. Wang reports no disclosures. Dr. Louis served on scientific advisory boards for the Brain Tumor Society and the Henry Ford Hermlin Brain Tumor Center; has received honoraria from Alnylam Pharmaceuticals and Biogen Idec; his department performs clinical testing for MGMT status and bills for the testing; receives royalties from publishing Greenfield's Neuropathology (Arnold Publishing, 2008–2009) and UpToDate (UpToDate Publishing, 2006–2009); receives research support from the NIH [RO1CA57683 (PI)] and the Simches Endowed Fund for Brain Tumor Research; and has served as an expert witness in brain tumor–related cases. Dr. Iafrate receives research support from AstraZeneca, Fidelity Foundation, and Aid for Cancer Research Foundation; and serves as a consultant for Pfizer, Inc. Dr. Batchelor is on the speakers' bureaus of Schering-Plough Corp. and Enzon Pharmaceuticals, Inc.; serves as consultant/on scientific advisory boards for Acceleron Pharma, AstraZeneca, EMD-Serono, Exelixis Inc., ImClone Systems, Genentech, Inc., Millennium Pharmaceuticals, Inc., and Vertex Pharmaceuticals; serves on the editorial boards of the Journal of Clinical Oncology and Oncologist; receives royalties from publishing UpToDate in Oncology (Up To Date, Inc. 2007–2009); has received non-industry-sponsored speaker honoraria; and receives research support from Millennium Pharmaceuticals, Inc., Schering-Plough Corp., and the NIH [KCA1254401 (PI), R01CA129371-01 (PI), 5K12CA90354-02 (Co-PI, PI), 1R13CA124293-01 (PI)]. ",

year = "2009",

month = nov,

doi = "10.1212/WNL.0b013e3181bf9907",

language = "English",

volume = "73",

pages = "1509--1510",

journal = "Neurology",

issn = "0028-3878",

number = "18",

}

TY - JOUR

T1 - MGMT methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma

AU - Gerstner, Elizabeth R.

AU - Yip, S.

AU - Wang, D. L.

AU - Louis, D. N.

AU - Iafrate, A. J.

AU - Batchelor, T. T.

N1 - Funding Information: Disclosure: Dr. Gerstner is funded by a K12 training grant (awarded to Dr. Batchelor). Dr. Yip is funded by a Royal College of Physicians and Surgeons of Canada Clinical Investigator Fellowship. D.L. Wang reports no disclosures. Dr. Louis served on scientific advisory boards for the Brain Tumor Society and the Henry Ford Hermlin Brain Tumor Center; has received honoraria from Alnylam Pharmaceuticals and Biogen Idec; his department performs clinical testing for MGMT status and bills for the testing; receives royalties from publishing Greenfield's Neuropathology (Arnold Publishing, 2008–2009) and UpToDate (UpToDate Publishing, 2006–2009); receives research support from the NIH [RO1CA57683 (PI)] and the Simches Endowed Fund for Brain Tumor Research; and has served as an expert witness in brain tumor–related cases. Dr. Iafrate receives research support from AstraZeneca, Fidelity Foundation, and Aid for Cancer Research Foundation; and serves as a consultant for Pfizer, Inc. Dr. Batchelor is on the speakers' bureaus of Schering-Plough Corp. and Enzon Pharmaceuticals, Inc.; serves as consultant/on scientific advisory boards for Acceleron Pharma, AstraZeneca, EMD-Serono, Exelixis Inc., ImClone Systems, Genentech, Inc., Millennium Pharmaceuticals, Inc., and Vertex Pharmaceuticals; serves on the editorial boards of the Journal of Clinical Oncology and Oncologist; receives royalties from publishing UpToDate in Oncology (Up To Date, Inc. 2007–2009); has received non-industry-sponsored speaker honoraria; and receives research support from Millennium Pharmaceuticals, Inc., Schering-Plough Corp., and the NIH [KCA1254401 (PI), R01CA129371-01 (PI), 5K12CA90354-02 (Co-PI, PI), 1R13CA124293-01 (PI)].

PY - 2009/11

Y1 - 2009/11

UR - https://www.scopus.com/pages/publications/70449440499

U2 - 10.1212/WNL.0b013e3181bf9907

DO - 10.1212/WNL.0b013e3181bf9907

M3 - Article

C2 - 19884580

AN - SCOPUS:70449440499

SN - 0028-3878

VL - 73

SP - 1509

EP - 1510

JO - Neurology

JF - Neurology

IS - 18

ER -

MGMT methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma

Access to Document

Other files and links

Cite this